240 related articles for article (PubMed ID: 9031992)
1. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal.
Monti JM; Monti D; Estévez F; Giusti M
Int Clin Psychopharmacol; 1996 Dec; 11(4):255-63. PubMed ID: 9031992
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Scharf MB; Roth T; Vogel GW; Walsh JK
J Clin Psychiatry; 1994 May; 55(5):192-9. PubMed ID: 8071269
[TBL] [Abstract][Full Text] [Related]
5. Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia.
Monti JM; Alvariño F; Monti D
Sleep; 2000 Dec; 23(8):1075-84. PubMed ID: 11145322
[TBL] [Abstract][Full Text] [Related]
6. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.
Herrmann WM; Kubicki ST; Boden S; Eich FX; Attali P; Coquelin JP
J Int Med Res; 1993; 21(6):306-22. PubMed ID: 8143886
[TBL] [Abstract][Full Text] [Related]
7. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia.
Perlis ML; McCall WV; Krystal AD; Walsh JK
J Clin Psychiatry; 2004 Aug; 65(8):1128-37. PubMed ID: 15323600
[TBL] [Abstract][Full Text] [Related]
8. Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients.
Monti JM; Attali P; Monti D; Zipfel A; de la Giclais B; Morselli PL
Pharmacopsychiatry; 1994 Jul; 27(4):166-75. PubMed ID: 7972349
[TBL] [Abstract][Full Text] [Related]
9. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
Roth T; Krystal A; Steinberg FJ; Singh NN; Moline M
Sleep; 2013 Feb; 36(2):189-96. PubMed ID: 23372266
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.
Voderholzer U; Riemann D; Hornyak M; Backhaus J; Feige B; Berger M; Hohagen F
Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):117-23. PubMed ID: 11697572
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
Walsh JK; Soubrane C; Roth T
Am J Geriatr Psychiatry; 2008 Jan; 16(1):44-57. PubMed ID: 18165461
[TBL] [Abstract][Full Text] [Related]
12. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.
Roehrs TA; Randall S; Harris E; Maan R; Roth T
J Psychopharmacol; 2012 Aug; 26(8):1088-95. PubMed ID: 22004689
[TBL] [Abstract][Full Text] [Related]
13. Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study.
Roehrs TA; Randall S; Harris E; Maan R; Roth T
Sleep; 2011 Feb; 34(2):207-12. PubMed ID: 21286241
[TBL] [Abstract][Full Text] [Related]
14. Eight weeks of non-nightly use of zolpidem for primary insomnia.
Walsh JK; Roth T; Randazzo A; Erman M; Jamieson A; Scharf M; Schweitzer PK; Ware JC
Sleep; 2000 Dec; 23(8):1087-96. PubMed ID: 11145323
[TBL] [Abstract][Full Text] [Related]
15. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
16. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
Elie R; Rüther E; Farr I; Emilien G; Salinas E
J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636
[TBL] [Abstract][Full Text] [Related]
17. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem.
Kryger MH; Steljes D; Pouliot Z; Neufeld H; Odynski T
Sleep; 1991 Oct; 14(5):399-407. PubMed ID: 1759092
[TBL] [Abstract][Full Text] [Related]
18. Zolpidem extended-release.
Moen MD; Plosker GL
CNS Drugs; 2006; 20(5):419-26; discussion 427-8. PubMed ID: 16696581
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of insomnia related to depressive disorders. Effects of zolpidem versus flunitrazepam administration and withdrawal evaluated in a double-blind study].
Guazzelli M; Ciapparelli A; Balsamo EL; Gemignani A; Sarteschi P
Minerva Psichiatr; 1993 Sep; 34(3):193-203. PubMed ID: 8302193
[TBL] [Abstract][Full Text] [Related]
20. Gender Differences in the Efficacy and Safety of Chronic Nightly Zolpidem.
Roehrs TA; Roth T
J Clin Sleep Med; 2016 Mar; 12(3):319-25. PubMed ID: 26446253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
